Sanofi: Annual General Meeting of April 30, 2019
30 Avril 2019 - 6:00PM
|
Press Release
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
|
Annual General Meeting of April 30, 2019
- Approval of the
financial statements for the fiscal year 2018
- Dividend of
€3.07 per share payable as of May 13, 2019
- Board
composition : renewals and ratification of a co-opting
director
Paris, France - April 30, 2019 - The Combined
General Shareholders' Meeting of Sanofi was held on April 30, 2019
at the Palais des Congrès in Paris, under the chairmanship of Serge
Weinberg. All resolutions submitted to the vote were adopted by the
shareholders.
The General Meeting approved,
among other resolutions, the individual Company and consolidated
financial statements for the fiscal year 2018. The General Meeting
decided the distribution of a cash dividend in the amount of € 3.07
per share with payment as of May 13, 2019.
The General Meeting also renewed
as Directors Suet-Fern Lee and Serge Weinberg and ratified the
co-opting of Christophe Babule.
Following the General Meeting, the
Board of Directors is still comprised of 16 members, of whom six
are women and two are Directors representing employees. The Board
of Directors remains for a large majority comprised of independent
Directors.
The voting results and the
audiocast of the Annual General Meeting are available on:
www.sanofi.com/AG2019
During the Board of Directors
session following the meeting, Serge Weinberg was renewed as
Chairman of the Board, Melanie Lee was appointed as member of the
appointment, governance and CSR Committee and Carole Piwnica was
appointed as member of the compensation Committee.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Quentin
Vivant
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
|
About
Sanofi
Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
Press release (pdf)
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024